Kalvista Pharmaceuticals Inc
F:4XC1
Kalvista Pharmaceuticals Inc
F:4XC1
Price:
23.01
EUR
Market Closed
Market Cap:
€978.4m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
K
|
Kalvista Pharmaceuticals Inc
F:4XC1
|
US |
|
C
|
China State Construction International Holdings Ltd
XMUN:C4S1
|
HK |
|
V
|
Voya Financial Inc
F:V0Y
|
US |
|
L
|
Lagardere SA
DUS:LAG
|
FR |
|
Ekso Bionics Holdings Inc
NASDAQ:CHRN
|
US |
|
Zura Bio Ltd
F:94E
|
US |
|
I
|
IDT Corp
F:IDC2
|
US |
Wall St Price Targets
4XC1 Price Targets Summary
Kalvista Pharmaceuticals Inc
Kalvista Pharmaceuticals Inc
Wall Street analysts forecast 4XC1 stock price to drop over the next 12 months.
According to Wall Street analysts, the average 1-year price target for 4XC1 is 10.55 EUR with a low forecast of 9.44 EUR and a high forecast of 13.08 EUR.
Lowest Forecast
Price Target
9.44
EUR
59% Downside
Average Forecast
Price Target
10.55
EUR
54% Downside
Highest Forecast
Price Target
13.08
EUR
43% Downside
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 4XC1's stock price target?
Price Target
10.55
EUR
10.55
EUR
According to Wall Street analysts, the average 1-year price target for 4XC1 is 10.55 EUR with a low forecast of 9.44 EUR and a high forecast of 13.08 EUR.
What is the Revenue forecast for Kalvista Pharmaceuticals Inc?
Projected CAGR
39%
39%
Over the last 12 years, the compound annual growth rate for Revenue has been 49%. The projected CAGR for the next 8 years is 39%.
